image
Healthcare - Drug Manufacturers - General - NYSE - US
$ 81.18
-0.356 %
$ 205 B
Market Cap
12.04
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MRK stock under the worst case scenario is HIDDEN Compared to the current market price of 81.2 USD, Merck & Co., Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MRK stock under the base case scenario is HIDDEN Compared to the current market price of 81.2 USD, Merck & Co., Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MRK stock under the best case scenario is HIDDEN Compared to the current market price of 81.2 USD, Merck & Co., Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MRK

image
$110.0$110.0$105.0$105.0$100.0$100.0$95.0$95.0$90.0$90.0$85.0$85.0$80.0$80.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
64.2 B REVENUE
6.74%
22.7 B OPERATING INCOME
668.18%
17.1 B NET INCOME
4593.97%
21.5 B OPERATING CASH FLOW
65.06%
-7.73 B INVESTING CASH FLOW
45.08%
-7.03 B FINANCING CASH FLOW
-46.20%
15.6 B REVENUE
-6.20%
6.82 B OPERATING INCOME
71.18%
3.74 B NET INCOME
18.44%
3.45 B OPERATING CASH FLOW
-62.87%
-1.44 B INVESTING CASH FLOW
62.44%
-3.01 B FINANCING CASH FLOW
-24.08%
Balance Sheet Merck & Co., Inc.
image
Current Assets 38.8 B
Cash & Short-Term Investments 13.7 B
Receivables 10.3 B
Other Current Assets 14.8 B
Non-Current Assets 38.5 B
Long-Term Investments 463 M
PP&E 0
Other Non-Current Assets 38 B
17.71 %13.30 %19.17 %49.22 %Total Assets$77.3b
Current Liabilities 28.4 B
Accounts Payable 0
Short-Term Debt 2.65 B
Other Current Liabilities 25.8 B
Non-Current Liabilities 42.3 B
Long-Term Debt 34.5 B
Other Non-Current Liabilities 7.85 B
3.75 %36.43 %48.72 %11.10 %Total Liabilities$70.7b
EFFICIENCY
Earnings Waterfall Merck & Co., Inc.
image
Revenue 64.2 B
Cost Of Revenue 12.3 B
Gross Profit 51.9 B
Operating Expenses 29.2 B
Operating Income 22.7 B
Other Expenses 5.56 B
Net Income 17.1 B
70b70b60b60b50b50b40b40b30b30b20b20b10b10b0064b(12b)52b(29b)23b(6b)17bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
80.85% GROSS MARGIN
80.85%
35.36% OPERATING MARGIN
35.36%
26.68% NET MARGIN
26.68%
36.96% ROE
36.96%
22.15% ROA
22.15%
37.86% ROIC
37.86%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Merck & Co., Inc.
image
20b20b18b18b16b16b14b14b12b12b10b10b8b8b6b6b4b4b2b2b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 17.1 B
Depreciation & Amortization 4.5 B
Capital Expenditures -3.37 B
Stock-Based Compensation 761 M
Change in Working Capital -3.67 B
Others 1.22 B
Free Cash Flow 18.1 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Merck & Co., Inc.
image
Wall Street analysts predict an average 1-year price target for MRK of $136 , with forecasts ranging from a low of $106 to a high of $148 .
MRK Lowest Price Target Wall Street Target
106 USD 30.57%
MRK Average Price Target Wall Street Target
136 USD 67.75%
MRK Highest Price Target Wall Street Target
148 USD 82.31%
Price
Max Price Target
Min Price Target
Average Price Target
15015014014013013012012011011010010090908080May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.77% DIVIDEND YIELD
0.81 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
3.500003.500003.000003.000002.500002.500002.000002.000001.500001.500001.000001.000000.500000.500000.000000.000000.429390.438930.448470.458020.524810.582060.620230.690.730.770.810.429390.438930.448470.458020.524810.582060.650.690.730.770.429390.438930.448470.458020.524810.582060.650.690.730.770.438931.730.448471.770.458021.800.524811.900.582062.160.620232.370.692.610.732.800.772.960.813.120.812015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Merck & Co., Inc.
image
Sold
0-3 MONTHS
1.44 M USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
1.58 M USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Merck & Co., Inc. (MRK) Shareholders NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=141528&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers. zacks.com - 1 week ago
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRK NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=141450&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=141406&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
MRK Stockholders Have Opportunity to Lead Merck & Co., Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or "the Company") (NYSE:MRK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Merck securities between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"). accessnewswire.com - 1 week ago
Shareholders that lost money on Merck & Co., Inc.(MRK) should contact The Gross Law Firm about pending Class Action - MRK NEW YORK , April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK). Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. prnewswire.com - 1 week ago
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRK NEW YORK, NY / ACCESS Newswire / April 6, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=141380&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
MRK DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - MRK NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Rosen Law Firm PA WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. accessnewswire.com - 1 week ago
Shareholders of Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK NEW YORK, NY / ACCESS Newswire / April 6, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=141344&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
MRK LAWSUIT ALERT: Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline NEW YORK, NY / ACCESS Newswire / April 6, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=141297&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Faruqi & Faruqi Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options globenewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE:MRK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. accessnewswire.com - 1 week ago
8. Profile Summary

Merck & Co., Inc. MRK

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 205 B
Dividend Yield 0.77%
Description Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Contact 2000 Galloping Hill Road, Kenilworth, NJ, 07033 https://www.merck.com
IPO Date Jan. 13, 1978
Employees 73000
Officers Mr. Richard R. DeLuca Jr. Executive Vice President & President of Merck Animal Health Mr. Dalton E. Smart III Senior Vice President of Finance, Principal Accounting Officer & Global Controller Ms. Caroline Litchfield Executive Vice President & Chief Financial Officer Ms. Cristal N. Downing Executive Vice President and Chief Communications & Public Affairs Officer Dr. Dean Y. Li M.D., Ph.D. Executive Vice President & President of Merck Research Laboratories Ms. Jennifer L. Zachary J.D. Executive Vice President & General Counsel Mr. Robert M. Davis J.D. Chairman, President & Chief Executive Officer Mr. Sanat Chattopadhyay Executive Vice President & President of Merck Manufacturing Division Mr. David Michael Williams Executive Vice President and Chief Information & Digital Officer Mr. Peter Dannenbaum Vice President of Investor Relations